Form 4: Viracta Therapeutics Director Ivor Royston Acquires 50,000 Stock Options

Director Ivor Royston acquired 50,000 stock options in Viracta Therapeutics, Inc. on June 20, 2024.

Summary

• On June 20, 2024, Ivor Royston, a director of Viracta Therapeutics, Inc. (VIRX), acquired 50,000 stock options.
• The exercise price of these options is $0.569.
• The options vest monthly over 12 months from the grant date, or fully at the next annual stockholder meeting, contingent on continued service.
• The options expire on June 20, 2034.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of stock option grants. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates changes in beneficial ownership by a company insider.

Stakeholder Impact

• The granting of stock options to a director may align their interests with those of shareholders, potentially incentivizing them to increase shareholder value.

Key Dates

Keywords

stock options, director, VIRX, Viracta Therapeutics, Form 4, beneficial ownership, Ivor Royston